Best of ASCO - 2014 Annual Meeting

 

Welcome

Pancreatic Cancer

Gastrointestinal (Noncolorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A clinical prediction model to assess risk for pancreatic cancer among patients with pre-diabetes.

Shimon Ben Boursi

e16226

A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).

Niall C. Tebbutt

e16231

A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).

Andrew Peter Dean

4111

A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.

Benjamin Adam Weinberg

TPS4150

A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.

Olatunji B. Alese

TPS4155

A phase II study of neodjuvant chemoimmunotherapy followed by stereotactic radiotherapy/nelfinavir in patients with locally advanced CA125 expressing pancreatic adenocarcinoma.

Chi Lin

e16202

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).

Alice Chia-chi Wei

4112

A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma.

Olumide B. Gbolahan

TPS4157

A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.

Manisha Palta

4121

A real-world multicenter analysis of first (1L) and second line (2L) treatment of advanced pancreatic adenocarcinoma (APC).

Irene S. Yu

e16210

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response.

Vincent M. Chung

TPS4154

A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.

Andrea Wang-Gillam

e16204

Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.

Walid Labib Shaib

4125

Applying evidence-based software for NGS in pancreatic cancer: First results from the PePaCaKa study.

Matthias Loehr

e16214

Association between changing body composition after diagnosis and survival of patients with advanced pancreatic cancer.

Michael Hayden Rosenthal

e16247

Chemotherapy and radiotherapy application for pancreatic cancer in Europe and USA: An international population-based study.

Lei Huang

4127

Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.

Belinda Lee

e16206

Clinical outcomes in borderline resectable pancreatic cancer (BRPC): A single institutional analysis.

Daniel Ezekwudo

e16232

Clinical presentation, treatment and outcome of a cohort of pancreatic ductal adenocarcinoma (PDA) patients in Mexico.

Vanessa Rosas Camargo

e16260

Combined effect of gemcitabine (GEM) and sapC-DOPS nanovesicles on pancreatic ductal adenocarcinoma (PDAC) in mice.

Xiaoyang Qi

e16209

Comprehensive molecular profiling of paired patient samples of primary and metastatic (met) pancreatic ductal adenocarcinoma (PDAC).

Neel Trivedi

4114

Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience.

Mandana Kamgar

e16236

Development and validation of a prognostic nomogram for metastatic pancreatic cancer.

Junjie Hang

e16220

DNA damage with liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts: Multimodal analysis of deposition characteristics.

Stephan G Klinz

e16205

DNA repair deficiency, genomic instability and immune profiling in a phase 1 study of locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and radiotherapy.

Richard Tuli

4128

Early outcomes of a high-risk cohort in pancreatic cancer surveillance.

Maria Fernanda Montiel

e16258

Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.

Vincent J. Picozzi

4016

Effect of inhibition of 15-PGDH on Kras-driven tumor expansion through all-trans retinoic acid metabolism in the pancreas.

Takatsugu Ishimoto

e16197

Effect of YAP1 on pancreatic stellate cell activation and tumor microenvironment.

Ying Xiao

e16199

Efficacy and safety of nab-paclitaxel plus s-1 in the first-line treatment of advanced pancreatic cancer.

Wen Zhang

e16217

Efficacy of pegvorhyaluronidase alfa (PEGPH20) plus FOLFIRINOX in a preclinical model of human pancreatic ductal adenocarcinoma.

Jesse Bahn

e16244

Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.

Marina Baretti

TPS4151

Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma.

Thomas J. George

4124

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Laetitia Dahan

4000

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

Julien Taieb

4107

Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in 1st line metastatic pancreatic cancer (MPC).

Vincent J. Picozzi

e16218

Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).

Talia Golan

4115

Germline variants from paired somatic-germline testing in pancreatic cancer.

Pauline Funchain

e16259

High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer.

Maria Fernanda Montiel

4129

HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

Eileen Mary O'Reilly

e16235

Identifying continuing educational needs among oncologists in managing patients with pancreatic cancer.

Wendy Cerenzia

e16233

Identifying the patient journey and treatment lines patterns in metastatic pancreatic cancer using patient-reported outcomes (PRO) from a digital patient-powered network (PPN).

Irad Deutsch

e16252

Impact of neoadiuvant treatment (NAT) in pancreatic adenocarcinoma (PDAC): Retrospective observational study in Pancreatic Cancer Registry of Reggio Emilia Province (REPCR).

Licia Baldi

e16213

Impact of nodal and margin status in pancreatic cancer patients undergoing surgery and chemotherapy: National Cancer Database analysis 2004-2014.

Sukamal Saha

e16223

Impact of venous thromboembolism among hospitalized pancreatic cancer patients: Results from national inpatient sample.

Ramesh Kumar Pandey

e16224

Independent prognostic value of inflammation in metastatic pancreatic cancer.

Berna Oksuzoglu

e16212

Intensification of induction chemotherapy before chemoradiotherapy improves progression-free survival in patients with locally advanced pancreatic cancers.

Nicolas Williet

e16221

Meta-analysis to identify emerging biomarkers of pancreatic adenocarcinoma pathogenesis.

Kamal Khorfan

e16239

Mutation profiling of cancer and stromal cells from patients with pancreatic ductal adenocarcinoma.

Liu Yang

e16238

Nab-paclitaxel plus S-1 followed by S-1 maintenance therapy as a first-line strategy for advanced pancreatic adenocarcinoma.

Yan Shi

4117

Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.

Quisette Janssen

e16207

Outcome driven persona-typing for precision oncology: Beyond a genomics centered view of individualized therapy.

Emanuel Petricoin

4130

Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

J. Randolph Hecht

4119

Palliative treatment of pancreatic adenocarcinoma in a real-world setting.

Maximilian Kordes

e16243

Perioperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis.

Elinor Tan

e16227

Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.

Kimberly Perez

TPS4152

Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).

Tanios S. Bekaii-Saab

4110

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.

Nathan Bahary

4015

Portal hypertension and ascites in pancreatic cancer.

Varun Yadav Roy

e16242

Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.

Janet E. Murphy

4116

Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program.

Emanuel Petricoin

4126

Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.

Geertjan Van Tienhoven

LBA4002

PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) – Part of Precision-Panc.

Janet Shirley Graham

TPS4158

Prognosis of resectable pancreatic cancer based on systemic therapy sequence and regimen: An NCDB analysis.

Aileen Deng

4120

Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.

Inna Chen

e16249

Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and S-1 (GS) for borderline resectable (BR)/unresectable (UR) pancreatic cancer (CAP-003 study).

Hideyuki Yoshitomi

e16225

Prospective trial of preoperative FOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma (PDAC): Report of early endpoints.

Safi Shahda

4118

Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal adenocarcinoma.

Thomas Enzler

4122

Real life data of 601 patients from the QoliXane pancreatic cancer study.

Caroline Schoenherr

e16248

Real world outcomes of metastatic pancreatic cancer (mPC) patients (pts) treated with liposomal irinotecan (nal-IRI) in the US.

Afsaneh Barzi

e16229

Relationship between desmoplastic pattern and lymphocytes infiltration in pancreatic cancer.

Takahiro Einama

e16245

Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.

Smita Suhas Joshi

e16241

Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).

Michael J. Overman

4123

Searching for circulating proteins as new biomarkers/potential therapeutic targets in advanced pancreatic cancer patients.

Roberto A. Pazo Cid

e16219

Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.

Eric Assenat

4109

SM-88 in advanced cancers of the pancreas (SMACP).

Marcus Smith Noel

TPS4156

Soluble urokinase plasminogen activator receptor (suPAR) as a serum biomarker for patients undergoing resection of pancreatic adenocarcinoma.

Sven H Loosen

e16203

Survival of patients with pancreatic cancer II-IV stages depending on the stage, regimen used in the first line.

Kristina A. Novoselova

e16211

Survival of resected and overall pancreatic cancer patients in Europe and USA in 2003-2014: An international large-scale population-based investigation.

Lei Huang

e16251

Survival trend among patients with advanced pancreatic neuroendocrine tumors in United States.

Ranju Kunwor

e16256

SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.

Davendra Sohal

TPS4153

Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody.

Lawrence G. Lum

4108

Ten year mortality trends among Israeli pancreatic ductal adenocarcinoma (PDAC) patients.

Leora Ferro

e16222

The prognostic impact of sarcopenic change after 8 weeks of 1st line gemcitabine based chemotherapy in advanced pancreatic adenocarcinoma.

In-Ho Kim

e16237

The role of radiation therapy to the primary site in locally advanced and metastatic pancreatic cancer ( 2004-2015 National Cancer Data Base (NCDB) review).

Nibal Saad

e16257

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Thierry Conroy

LBA4001

Universal screening for mismatch repair deficiency in pancreatic cancer.

Aser Abrha

e16254